Medtronic to market Powerheart hospital monitor:
This article was originally published in Clinica
Medtronic Physio-Control is to market Cardiac Science's Powerheart fully automatic hospital bedside defibrillator-monitor in the US and Canada. Medtronic has also gained an exclusive licence for the Irvine, California-based company's proprietary tachyarrhythmia detection and discrimination software. Medtronic will integrate the software into existing and future LIFEPAK defibrillator/monitor products for the US and Canadian hospital market. Medtronic Physio-Control is Medtronic's defibrillator division - formed after Medtronic's acquisition of Physio-Control earlier this year.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.